Wisconsin Alumni Research Foundation

Therapeutics & Vaccines
Therapeutics Vaccines
Biocompatible Formulations of Poorly Soluble Anticancer Drugs Such as Gossypol
WARF: P100278US02

Inventors: Glen Kwon, Ho-Chul Shin, Hyunah Cho

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing stable and biocompatible drug formulations that improve the bioavailability of combinations of poorly soluble drugs like gossypol, paclitaxel, 17-AAG and cyclopamine without causing toxicity.
Many powerful drugs have only limited usefulness because they are relatively insoluble in aqueous solutions. For example, gossypol has been identified as an effective inhibitor of Bcl-2 proteins, which play a role in apoptosis, but is difficult to deliver to tumor sites in vivo because of its low solubility.

In addition, many cancer treatment strategies have shifted to combination drug therapy. It's hoped that the ability to safely and simultaneously deliver multiple drugs to target several cancer-related pathways at one time will improve the efficacy of treatment. However, combining two or three drugs can be challenging in clinical practice due to the differing solubilities and modes of delivery of the therapeutics.
The Invention
UW–Madison researchers have developed biocompatible micelles loaded with gossypol or combinations of gossypol and other anticancer drugs such as paclitaxel, 17-AAG and cyclopamine. These drug formulations are stable and provide improved bioavailability without causing toxicity. They enable the intravenous delivery of cancer therapeutics like gossypol that are poorly soluble in water.
  • Drug delivery
  • Cancer treatment
Key Benefits
  • Enables safe and simple intravenous delivery of gossypol or combinations of gossypol and other anticancer therapeutics
  • Effectively solubilizes drug combinations without the need for additional, potentially toxic surfactants
  • Provides a drug delivery system capable of solubilizing Bcl-2 inhibitors such as gossypol
  • Micelles may consist of poloxamer 188, which is biocompatible and an FDA-approved polymer.
Additional Information
For More Information About the Inventors
For current licensing status, please contact Rafael Diaz at [javascript protected email address] or 608-960-9847